D.E. Shaw & Co
KERX

D.E. Shaw & Co’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

D.E. Shaw & Co’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-16,921
Closed -$79K – 3928
2017
Q4 		$79K Sell
16,921
-264,379
-94% -$1.46M ﹤0.01% 3511
2017
Q3 		$2M Buy
281,300
+111,721
+66% +$803K ﹤0.01% 2024
2017
Q2 		$1.23M Buy
169,579
+43,011
+34% +$269K ﹤0.01% 2285
2017
Q1 		$780K Sell
126,568
-53,703
-30% -$294K ﹤0.01% 2475
2016
Q4 		$1.06M Buy
180,271
+152,588
+551% +$834K ﹤0.01% 2421
2016
Q3 		$147K Sell
27,683
-1,569
-5% -$8.46K ﹤0.01% 3247
2016
Q2 		$194K Sell
29,252
-230,968
-89% -$1.29M ﹤0.01% 3196
2016
Q1 		$1.22M Buy
260,220
+102,995
+66% +$411K ﹤0.01% 2235
2015
Q4 		$794K Buy
157,225
+38,664
+33% +$184K ﹤0.01% 2804
2015
Q3 		$417K Sell
118,561
-67,159
-36% -$450K ﹤0.01% 3177
2015
Q2 		$1.85M Buy
185,720
+173,805
+1,459% +$1.86M ﹤0.01% 2256
2015
Q1 		$152K Sell
11,915
-76,664
-87% -$986K ﹤0.01% 3488
2014
Q4 		$1.25M Buy
88,579
+34,340
+63% +$532K ﹤0.01% 2653
2014
Q3 		$746K Buy
54,239
+20,651
+61% +$316K ﹤0.01% 3048
2014
Q2 		$517K Sell
33,588
-39,753
-54% -$563K ﹤0.01% 3504
2014
Q1 		$1.25M Sell
73,341
-641,932
-90% -$9.69M ﹤0.01% 2836
2013
Q4 		$9.26M Buy
715,273
+211,206
+42% +$2.52M 0.01% 1199
2013
Q3 		$5.09M Sell
504,067
-187,557
-27% -$1.67M 0.01% 1568
2013
Q2 		$5.17M Buy
+691,624
New +$5.4M 0.01% 1334

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

D.E. Shaw & Co's KERX Position: Q1 2018 in Review

D.E. Shaw & Co sold out of Keryx Biopharmaceuticals Inc (KERX) in Q1 2018, closing a stake of 16,921 shares — an estimated $79K sold.

D.E. Shaw & Co first reported a position in KERX in Q2 2013 and held it in 19 quarters. The position peaked at $9.26M in Q4 2013. 125 funds tracked by Wall St. Rank hold KERX as of Q1 2018.

  • D.E. Shaw & Co reported no remaining Keryx Biopharmaceuticals Inc position as of Q1 2018 after selling out during the quarter.
  • D.E. Shaw & Co sold 16,921 Keryx Biopharmaceuticals Inc shares in Q1 2018, an estimated $79K.
  • D.E. Shaw & Co first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 19 quarters.
  • D.E. Shaw & Co's Keryx Biopharmaceuticals Inc position peaked at $9.26M in Q4 2013.
  • 125 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2018.

Based on D.E. Shaw & Co's 13F filing for Q1 2018, filed 15 May 2018.